This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Telik Announces Telintra® Clinical Publication At The 54th Annual Meeting Of The American Society Of Hematology

PALO ALTO, Calif., Dec. 12, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the publication of a clinical trial abstract in the proceedings of the 54 th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.  The abstract, " Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)," by Roger M. Lyons, MD; Sharon T. Wilks, MD; and of David J. Friedman MD, PhD, of Cancer Care Centers of South Texas, US Oncology in San Antonio, Texas; and Shelby A. Young, RN, BSN, and Gail L. Brown, MD, of Telik, Inc., in Palo Alto, California, is available online at Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4394.

This abstract reports the preliminary results of a clinical trial with ezatiostat to study the treatment of patients with idiopathic chronic neutropenia (ICN).  ICN is a rare group of blood disorders characterized by low circulating neutrophils, recurrent fevers, mucosal inflammation and serious systemic infections.  The risk and severity of these complications is related to abnormally low levels of white blood cells.  Most patients initially respond to treatment with granulocyte colony stimulating factors (G‑CSF); however, some patients fail to respond or become resistant to G‑CSF treatments.  Further, G‑CSF therapy is often associated with bone and muscle pain, low platelet counts and enlargement of the spleen.  Patients may need to be on G‑CSF for the rest of their lives, and these side effects can interfere with therapy.

Ezatiostat is an investigational agent in development for the treatment of ICN.  The compound is a glutathione S-transferase (GST) inhibitor that activates Jun kinase, which has been demonstrated to promote growth and maturation of hematopoietic progenitors.  Four patients with longstanding, severe ICN and inadequate absolute neutrophil count (ANC) response to G‑CSF were enrolled in this phase 2 trial.  These patients all had a history of frequent hospitalization for sepsis, prolonged courses of antibiotics and poor response to myeloid growth factors, including G‑CSF.  The patients were treated with orally administered ezatiostat.

Ezatiostat treatment of these ICN patients with grade 4 neutropenia who were not responsive to G‑CSF resulted in a durable increase in their white-blood-cell levels, leading to clinically significant reductions in serious infections.  Extended oral treatment with ezatiostat has been well tolerated in these patients and may be appropriate for longer-term therapy.  Ezatiostat is the first targeted GSTP1-1 inhibitor that has been shown to have a positive effect on white blood cell levels in ICN and may provide molecular insight into the pathophysiology of ICN.  These results suggest that further study is warranted of ezatiostat's potential role as an oral therapy alternative or adjunct to G‑CSF in the treatment of ICN in patients who are not responsive to G‑CSF.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs